Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings by Ushma Mehta et al.
Mehta et al. BMC Pregnancy and Childbirth 2012, 12:89
http://www.biomedcentral.com/1471-2393/12/89STUDY PROTOCOL Open AccessProtocol for a drugs exposure pregnancy registry
for implementation in resource-limited settings
Ushma Mehta1, Christine Clerk2, Elizabeth Allen3, Mackensie Yore4, Esperança Sevene5, Jan Singlovic6,
Max Petzold7, Viviana Mangiaterra8, Elizabeth Elefant9, Frank M Sullivan10, Lewis B Holmes11 and Melba Gomes8*Abstract
Background: The absence of robust evidence of safety of medicines in pregnancy, particularly those for major
diseases provided by public health programmes in developing countries, has resulted in cautious recommendations
on their use. We describe a protocol for a Pregnancy Registry adapted to resource-limited settings aimed at
providing evidence on the safety of medicines in pregnancy.
Methods/Design: Sentinel health facilities are chosen where women come for prenatal care and are likely to come
for delivery. Staff capacity is improved to provide better care during the pregnancy, to identify visible birth defects
at delivery and refer infants with major anomalies for surgical or clinical evaluation and treatment. Consenting
women are enrolled at their first antenatal visit and careful medical, obstetric and drug-exposure histories taken;
medical record linkage is encouraged. Enrolled women are followed up prospectively and their histories are
updated at each subsequent visit. The enrolled woman is encouraged to deliver at the facility, where she and her
baby can be assessed.
Discussion: In addition to data pooling into a common WHO database, the WHO Pregnancy Registry has three
important features: First is the inclusion of pregnant women coming for antenatal care, enabling comparison of
birth outcomes of women who have been exposed to a medicine with those who have not. Second is its
applicability to resource-poor settings regardless of drug or disease. Third is improvement of reproductive health
care during pregnancies and at delivery. Facility delivery enables better health outcomes, timely evaluation and
management of the newborn, and the collection of reliable clinical data. The Registry aims to improve maternal
and neonatal care and also provide much needed information on the safety of medicines in pregnancy.
Keywords: Pregnancy Registry, Congenital anomaly, Pharmacovigilance, Teratogenicity, Drug exposure,
Antiretrovirals, Antimalarials, Birth defects, Neonates, Safety, Resource-limited settingsBackground
Efforts to increase access to medicines for major diseases
such as malaria, HIV/AIDS, pneumonia and tuberculosis,
have accelerated. Novel life-saving therapies such as
artemisinin-based combination therapies (ACTs), antire-
trovirals (ARVs), anti-infectives and vaccines have been
introduced on a large scale [1]. However, the safety of
some of these therapies during pregnancy is unknown.
In some infections (HIV/AIDS, malaria), failure to
treat effectively may result in death, disease transmission
or poor outcomes for the mother and/or the baby.* Correspondence: gomesm@who.int
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reproduction in any medium, provided the orHowever the medicines themselves may cause toxicity,
including birth defects. Therefore, knowledge about the
risks of medicines during each trimester of pregnancy is
essential in order to assist patient management.
Animal studies suggest that the artemisinins as a
class (artesunate, dihydroartemisinin, artemether and
arteether) interfere with red blood cell formation and
can cause fetal loss at low dose levels. If administered
during early embryogenesis, congenital malformations
may also be induced [2,3]. The time window of sensitivity
observed in animal studies would correspond in humans
to part of the first trimester, during organogenesis. How-
ever, the period of erythroblast expansion in rodents that
is sensitive to the artemisinin damage occurs over a very
short period of about one day. In primates and humans itLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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three-day course of artemesinin treatment may not be
long enough to cause extensive damage. This may be the
reason why no such cases have been reported in humans
[4,5].
With efavirenz (EFV), central nervous system malfor-
mations have been observed in primates at doses com-
parable to systemic human exposure and although
retrospective case reports in humans exposed to EFV
show similar defects, a causal relationship has not been
established. A recent meta-analysis of data describes the
incidence of neural tube defects in the babies of women
receiving EFV during the first trimester (0.7%) to be no
higher than the incidence in babies born to women on
ARV regimens not containing EFV [6]. Although reassur-
ing, the limited sample of observations does not eliminate
this risk. Concerns have also been raised about the effect
of tenofovir on growth restriction and severe bone tox-
icity in pre-clinical primate and clinical studies [7].
The WHO treatment guidelines for malaria and HIV/
AIDS reflect these concerns about potential risk during
pregnancy [8,9]. In practice, pregnant women in coun-
tries with high burden of infections are likely to be
exposed to both medicines since the number of preg-
nancies among HIV-positive women already on ARVs is
increasing in both developed [10] and developing coun-
tries [11] and many pregnancies are unplanned. At the
same time, changes in drugs delivered across the care
continuum (antenatal, delivery, postpartum) pose oper-
ational challenges in high-burden low-resource settings.
WHO’s 2012 programmatic update for prevention of
mother to child transmission (PMTCT) points out that,
although concerns remain about EFV and monitoring is
necessary, triple ARV treatment under Option B and
Option B + (CD4 testing needed and desirable, respect-
ively) has benefits at the primary care level. It provides
greater assurance that women in need of treatment re-
ceive a fully suppressive regimen that minimizes risk of
infant infection and maximizes their own health benefit
[12]. In confirmed and unconfirmed diagnoses of mal-
aria, the artemisinins are being used extensively without
knowledge of pregnancy status in women of childbearing
age. Thus the likelihood of first trimester exposures to
medications for malaria and HIV has increased and is
expected to increase even more [13], making a preg-
nancy exposure registry essential.
Guidelines distinguish pregnancy registries from other
post-marketing surveillance techniques in that pregnant
women are enrolled before the outcome of the preg-
nancy is known[14], and many outcomes can be moni-
tored. If the purpose of the registry is to establish any
additional risk of birth defects for a particular drug,
pregnancy outcomes of women exposed to the drug/s
must be compared with outcomes of women who do nothave the disease and were not exposed to the medica-
tions of interest. The possibility of confounding by indi-
cation might also be addressed by assessing differences
in risk associated with different medicines used for the
same clinical condition, e.g. different ARVs for HIV.
Moreover, the data would allow for the assessment of
risk of multiple infections in pregnancy including sexu-
ally transmitted diseases, tuberculosis, malaria and HIV/
AIDS. Prospective monitoring is critical to reduce the
likelihood of selection and recall bias and to obtain reli-
able information on drug exposure and other risk fac-
tors. In most disease-endemic settings where ARVs and
ACTs are used, the background risk of congenital anom-
alies and other adverse pregnancy outcomes is not
known. [15]
We describe a Pregnancy Registry protocol to provide
evidence on the risk of increased prevalence of clinically
important malformations at birth associated with medi-
cines to which women might be exposed. The protocol
is neither disease nor drug-specific; this confers substan-
tial advantages for wider use of the same dataset. Its
methods, case record forms (CRFs) and training materi-
als (including a DVD showing how to conduct a surface
examination of a newborn) have been tested for feasibil-
ity in five countries (four in Africa and one in South
America). They have been refined as a consequence. The
approach is integrated within the reproductive health
system of the country, specifically ANC clinics and
labor/delivery facilities. The protocol builds on the fact
that in most African countries 90% of women access
health care during pregnancy, and malaria treatment,
HIV counseling and testing and PMTCT programmes
have good links with reproductive health services. It
assumes that individual countries and sentinel sites will
contribute to a pooled WHO database on safety of medi-
cations in pregnancy, and that materials developed by
WHO for use are available to any country wishing to
join, on condition that there is a commitment to train
the staff to use these materials to obtain reliable data on
drug exposure and to conduct a systematic surface
examination of the newborn. The Registry builds cap-
acity within the health system to improve maternal and
neonatal care as well as to serve as a sentinel surveil-
lance system for the safety of medicines used in preg-
nant women.
The specific objectives of the WHO Pregnancy Registry
are
1. To build capacity to obtain reliable information on
obstetric, medical, and drug history during pregnancy
and diagnose, assess, monitor and manage pregnancy
and the outcomes of pregnancy including congenital
malformations, stillbirths and prematurity.
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malformations in the absence of drug exposure
during the course of pregnancy.
3. To quantify the risk of major congenital
malformations associated with exposure to medicines
during the course of pregnancy.
4. To identify other obstetric, therapeutic and clinical
factors that may contribute to the risk of major
congenital anomalies and other adverse birth
outcomes in pregnant women.
5. To support a culture of drug safety awareness among
women and their providers in participating countries
and avoid preventable adverse drug-related
pregnancy outcomes.
6. To develop an ongoing surveillance system of maternal
and newborn health that strengthens the health
system to improve maternal and neonatal outcomes.
The primary endpoint is major external/visible con-
gential anomalies and the secondary endpoint is other
adverse birth outcomes including stillbirth, prematurity
and neonatal death within 24 hours of birth.
Methods/Design
This Pregnancy Registry is a prospective observational
cohort study that enrols pregnant women at their first
antenatal visit to a selected health facility. To obtain a
more accurate medical and drug exposure history, early
enrollment is desirable.
Study Population
The population of interest is pregnant women at
selected antenatal clinics (ANCs). These clinics are
chosen because of their location in areas with a high
prevalence of the disease of interest (i.e. where women
are likely to be exposed to the drug/s in question). In
addition, women presenting to these facilities should be
very likely to initiate antenatal care early in pregnancy
and deliver at the facility. All pregnant women seeking
care for the first time during their current pregnancy are
eligible. However, if there is a very high case-load at a fa-
cility, a random sampling method might be devised.
Thus, the number of women recruited at any facility will
depend on practical considerations such as available staff
capacity, attendance rates, facility delivery rates, and
willingness of women to consent to being followed to
term.
Country-sites fulfilling the following criteria would be
ideally placed to contribute to the Registry database.
 Strong commitment to the Registry from the
relevant departments of the Ministry of Health,
particularly Reproductive health and disease control
programmes (eg malaria and HIV/AIDS). Written agreement to pool all data derived from the
Pregnancy Registry into the WHO International
Registry database.
 A moderate to high prevalence of the disease of
interest with drugs of interest in common use for
these diseases (e.g. HIVAIDS, malaria, etc).
 Good antenatal, labor/delivery and diagnostic
services, and a willingness of staff to be trained to
improve reproductive care.
 Early ANC care attendance at the clinic.
 High attendance at delivery at the health facility.
(This increases the likelihood of a skilled assessment
of the child at birth). OR
 A reliable plan to follow-up women delivering at
home, and assess the child (e.g community health
nurses/midwives to monitor home deliveries).
 Identification of a local pediatrician or doctor and
commitment of such a person to review births and
photographs of births and advise on management of
infants. OR
 Identification, where possible, of a local specialist in
the diagnosis and management of congenital
anomalies.
 Identification of record-linkage systems between
general out- or in-patient records and specialized
clinics such as HIV clinics.
The approach described in this protocol establishes
the baseline risk of poor birth outcomes (miscarriages,
deaths, congenital anomalies, premature delivery, low
birth weight) and enables calculation of additional risk
of mortality or morbidity associated with specific dis-
eases with or without exposure to specific drugs. Pooling
data from different countries strengthens interpretation
of findings beyond a single population or geographical
location and enables detection of small or moderate
risks in a larger population.
Staff training
A sound obstetric, medical and drug history requires a
systematic approach by health staff. A training package
has been developed and includes modules to address the
following:
– How to obtain informed consent, if required
– How to obtain a comprehensive medical, drug and
obstetric history from pregnant women
– How to perform and record the findings of maternal
physical exams
– How to encourage women to attend follow-up visits
as recommended in national guidelines
– How to encourage women to deliver at the health
facility
– How to capture data in the Registry database
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women and newborns
– How to examine a newborn infant and take a digital
photograph for expert assessment (An instructional
video has been developed as a tool to teach the
systematic newborn surface examination).
– How and when to seek or refer a child for specialist
clinical or surgical management.
Recruitment and first antenatal visit
In the African region, 18 countries report ANC attend-
ance rates of ≥ 90% for at least one prenatal visit, with
only 4 countries reporting a rate below 50% [16]. Hence,
women in many parts of Africa can be enrolled at their
first ANC visit as a representative sample of the preg-
nant population seeking care. Figure 1 provides a flow
diagram of the study procedures from the initial visit at
the sentinel site to the national/regional registry.
Depending upon staff capacity, attendance rates and
case-load, a decision should be made on whether to enroll
all women who meet the inclusion criteria or a random
sample of these women (e.g. 1 day per week, or first 2
new ANC cases per day). A second decision is whether all
consenting pregnant women exposed to a drug of particu-
lar current interest, or with the particular condition of
interest, should be considered for enrollment irrespective
of the random selection process.
At her first ANC visit, a woman’s obstetric and med-
ical history is documented, including treatments and
laboratory tests for acute or chronic conditions (e.g. dia-
betes, epilepsy, HIV, malaria), and referrals to higher
levels of care made for specific checks as necessary. Data
on routine treatments to be provided during pregnancy,Figure 1 Flow diagram of study procedures.including iron and folic acid, are collected and the
woman is encouraged to return at scheduled ANC
appointments for further checks and updated documen-
tation on the pregnancy. She is encouraged to give birth
at the healthcare facility to reduce the risk of adverse
outcomes for herself and her baby, and to enable exam-
ination of the newborn by trained staff. If enrolled
women do not return for ANC visits or deliver at the
sentinel health facility within the expected period of time
after a scheduled ANC visit or delivery date, they are fol-
lowed up by phone or at home. This encourages facility
attendance during the pregnancy. In the case of a home
delivery it enables the pregnancy outcome to be docu-
mented. After home births, women are encouraged to
return to the health facility with their infants for an
examination and, if needed, medical care.
Loss to follow-up of enrollees constitutes a limitation of
the Registry because it will not be known whether the
participants lost have the same outcomes as those who re-
main under observation. Losses to follow-up can be mini-
mised by training health staff responsible for intake to
record detailed contact information of the women, coun-
selling them about the importance of follow-up antenatal
visits and delivering at the facility and providing women
with a contact number at the clinic to inform nurses
about any moves to travel, changes in their condition).
A final requirement is to identify a national, or prefer-
ably a local, neonatologist who can be contacted (by
telephone) to advise on the management of a newborn
requiring immediate clinical or surgical attention.
Participants voluntarily agreeing to participate should
be enrolled at the chosen sentinel sites using the follow-
ing inclusion and exclusion criteria:
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All of the following conditions must be met for
enrolment:
 A confirmed pregnancy (by physical examination,
pregnancy test or ultrasound)
 Presentation at the first antenatal visit for the
current pregnancy
 Information on presence/absence of fetal
abnormality unknown at the time of enrolment.
 Voluntary agreement by the woman to be followed
up to term.
Exclusion criteria
Meeting any of the following criteria would exclude a
woman from enrolment:
 Refusal to participate in the Registry
 Presence of a medical, psychiatric, or social
condition that interferes with the woman’s ability to
provide an accurate medical or drug history or give
informed consent (e.g. mentally disabled patients)
 Women who report that they will not give birth at
the health facility.
A coloured, visible sticker may be placed on the ANC
card of women meeting the selection criteria. The sticker
signals that facility staff must fill out CRF1 (see Additional
file 1) at the first visit and update it at each subsequent
visit and perform a physical exam on the infant when the
woman delivers.
The Registry CRF1 includes a more detailed history
than standard ANC information, but otherwise all proce-
dures routinely carried out at ANC in accordance with
national guidelines are conducted without modification.
It documents demographic data, medical history, obstet-
ric history, infections, drugs and vaccine use, intermittent





Medical & Obstetric History X
Physical Exam X
Counselling & assessment of concurrent illnesses
(HIV, anaemia etc.)
X
Drug exposure history X
Adverse outcomes in the mother X
Labor/Delivery
Physical Assessment of infant
Adverse Events in the mother and infantCRF1 establishes whether the woman has had exposure
to the medicine/s of interest, the timing of exposure and
whether the exposure took place on the basis of a clinical
or laboratory confirmed diagnosis. Various aids are intro-
duced at the sentinel sites to improve women’s recall of
drug exposures during pregnancy- including tablet and
treatment package visual identification kits, treatment
diaries or medicine storage sleeves. These recall aids are
utilized at the initial and follow-up ANC assessments.
Where possible, drug exposure is verified through record
linkage with other systems. Results of any tests or clinical
assessments are recorded. These could include voluntary
counseling and testing for HIV, assessment of weight,
height, gestational age, presence of chronic diseases or
conditions such as diabetes, syphilis and anaemia, and
pharmaceutical medications taken during or just before
the current pregnancy. Table 1 provides an overview of
the procedures and assessments to be conducted during
each of the facility visits during a woman’s pregnancy.
Second and subsequent antenatal visits
At the end of each ANC visit, an appointment for the
next ANC visit is made and contact details of the woman
are taken and updated when necessary. Women are asked
to return for follow-up assessments as normally sched-
uled, generally at least four ANC visits for each preg-
nancy. Updated information on the woman’s obstetric
and medical conditions, medication use, smoking and al-
cohol consumption are also obtained during follow-up
ANC visits (CRF 1). At each ANC visit the woman is
counseled to return to the facility for delivery.
Labor and Delivery
The labor/delivery ward staff identifies Registry enrollees
by the brightly coloured labels on the ANC cards. Imme-
diately after delivery, the baby (whether alive or stillborn)
will undergo a careful physical surface examination and
the details recorded on a Pregnancy Outcome CRFd procedures conducted during antenatal and
ment Second and
subsequent visits
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information on any abortions or miscarriages which ter-
minate the pregnancy. The vital status of the infant is
recorded as well as sex, head circumference, length and
weight. The date, place and time of examination and the
age of the baby at examination (number of days since
birth) is documented on CRF2 , so that analysis can sep-
arate babies assessed at birth from those assessed some
time later. Any abnormalities observed and any adverse
outcomes in the mother or baby are noted and reported
in the CRF.
Training materials have been developed to support
antenatal facility staff and delivery staff, to complete the
CRFs and to assess a newborn. The systematic surface
examination, as outlined in the training video, identifies
congenital anomalies which are visible to the examiner.
Some of these could be of major surgical or clinical im-
portance (refer to the section below on ascertainment
and classification of outcome). Digital photographs of
any abnormality are taken for the purposes of confirm-
ation and classification by an international Birth Defect
Panel. For the process of confirming birth defects, see
the section on ascertainment of outcome and Figure 2.
Photographs will not be taken if a mother refuses to
have a photograph taken of her infant at the time of birth
even if she had agreed to do so earlier. Her decision is
recorded on CRF2. Infants with major anomalies are re-
ferred to a specialist for confirmation of the diagnosis
(see CRF 3 – Additional file 3) and further management.
It is not expected that all staff performing deliveries in
resource-limited settings, usually nurses/midwives, can
auscultate for heart murmurs nor is it assumed that as-
sessment of other internal problems through ultrasoundFigure 2 Assessment process for congenital anomalies.equipment will be routinely available. The Registry does
not require that the palate be examined for oral clefts
nor that the hips be examined for congenital hip dyspla-
sia. Consequently, these important malformations will
not be detected unless clinical signs are noted and fur-
ther tests are performed.
If a woman does not deliver at the facility, arrange-
ments need to be made to carry out the surface examin-
ation as soon as possible after birth. In resource-limited
settings, where home-based delivery rates can be high
and referral systems inefficient, completion of the initial
examination and follow-up on findings within 12 weeks
is considered acceptable, especially if the examination is
done at a facility. A community health nurse can be
taught to conduct home assessments for women who
do not come to the facility to deliver. Community-
based staff would need to be adequately trained and
equipped to ensure that off-site assessments are equiva-
lent to facility-based assessments, especially if many
assessments are likely to be home-based. Although
home-based follow-up is important, the high rates of
facility-based BCG vaccinations even in the poorest
areas of Africa, suggests that a facility assessment can
be undertaken at the time of the first vaccination.
Losses to follow-up and un-assessed or uninvestigated
neonatal deaths or birth defects represent a limitation,
of the Registry as the possibility of infanticide or neglect
could occur if the newborn has a visible abnormality
such as clubfoot, cleft lip or myelomeningocele [17].
Ethics
The WHO Ethics Review Committee and the ethics
committees of the 5 participating countries (Brazil,
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pilot study have reviewed and approved the protocol for
use. Any site or country wanting to implement the
protocol can do so and establish whether local/national
ethics approval is required.
Investigators, in consultation with public health offi-
cials and ethics review committees, should determine
whether the Registry will be required to take informed
consent from enrollees and, if so, whether written or
verbal consent is appropriate.
Some ethics committees may waive the need for writ-
ten informed consent on the basis that:
i) the research is observational, part of standard of
care and involves no additional risk;
ii) a waiver does not adversely affect the rights and
welfare of the subjects;
AND
iii) the subjects will be provided with pertinent
information, if appropriate, after analysis [18].
In settings where the Registry is seen as part of a gov-
ernment program evaluating treatment policy for high
priority diseases in the country, a waiver may be sought
since written informed consent increases the time spent
with each woman at ANC and can reduce time for pa-
tient care.
Participation in the Registry is voluntary. Hence, if a
woman refuses to be part of the Registry, she can do so
without consequence to her medical care. If a woman
refuses to have a digital photograph taken of her infant
(i.e. in the case of a malformation), her data may be
included without photographs, with her agreement.
The woman must be assured that all information is kept
confidential and that her identity will be anonymized
when data are analyzed. A guidance note is provided to
women on the safe use of medicines in pregnancy in
order to engender confidence in the medicines being pre-
scribed for her during her pregnancy and the need for ex-
ercising caution when using over-the-counter and other
un-prescribed medicines (Additional file 4).
Clinical staff at participating health facilities are
trained to rapidly identify and refer infants with adverse
birth outcomes or birth defects to the appropriate med-
ical providers or healthcare facilities, to improve neo-
natal outcomes. However, each participating facility
must decide how to cover referral and treatment costs.
All significant findings from analyses need to be com-
municated to sentinel site staff on an ongoing basis.
Should any information come to light, which may dir-
ectly or indirectly benefit or harm the patient, the
attending clinician or health care provider should be
informed as soon as possible (e.g. if a baby is born with
a hereditary or potentially preventable birth defect themother may need counselling, or if it is noticed that a
clinic is prescribing inappropriate medication to preg-
nant women). The woman should be informed that
anonymized information from all countries will be
pooled in a relational online database and the findings
shared with the facility.
Ascertainment and classification of outcome
An International Birth Defects Assessment Panel has
been established by WHO to review, confirm and classify
major birth defects reported by the participating sites. Al-
though all birth defects are documented, exclusion cri-
teria have been developed by the Panel on the categories
of birth defects which are not relevant. All defects that do
not constitute “major malformations” defined as a struc-
tural abnormality with surgical, medical or cosmetic im-
portance and hereditary and chromosomal disorders that
are not caused by exposure to drugs, are excluded.
The following features/anomalies are therefore
excluded from the primary endpoint of assessing
drug-related risk [19]:
 minor anomalies ( e.g. transverse palmar crease)
 normal variations (e.g. umbilical hernia in African
infants)
 hereditary disorders (e.g. polydactyly, postaxial
Type B)
 birth marks (e.g. haemangiomas; congenital moles)
 chromosome abnormalities (e.g. Down syndrome)
 positional deformities (e.g. congenital hip dislocation
in infants who are born in breech position;
 features of prematurity (e.g. undescended testes and
patent ductus arteriosus in infants less than
37 weeks gestational age;
 biochemical abnormalities(e.g. carriers of cystic
fibrosis, and abnormal haemoglobins that may be
identified during newborn screening.
Monitoring and quality control
Progress and training of staff needs to be monitored
regularly for quality and reliability of procedures, exami-
nations and data. This will reduce the possibility of
biases in enrolment and the risk of false negative results
(e.g. when a surface examination of a baby was not
complete). Detection of the presence/absence of malfor-
mations depends upon the training, skill, and experience
of the assessor. Absence of malformations will not be re-
assuring, nor will data be reliable if assessors have not
looked for them or are unable to assess a child. Only re-
liable data should contribute to national policy. For this
reason it is recommended that a random sample of 5%
of all pregnancy outcomes be re-evaluated by a second
nurse and the comparison of these separate findings be
recorded.
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The cohort study design allows for analysis of the data
using three approaches – 1) as a complete cohort, 2)
using a case–control approach and 3) using a case-
cohort approach. The cohort analysis facilitates examin-
ation of the demographic and clinical information about
the mothers and infants and prevalence of risk factors
such as drug exposures during a particular trimester.
Case–control studies can be performed to determine the
risk of specifically defined birth defect/s (e.g. neural tube
defects) and whether or not these are associated with in-
utero exposure to particular medicines. A case-cohort
analysis approach can be used to test hypotheses not ini-
tially considered when the cohort was initiated or to
analyze data where additional assessments have been
carried out. Using this approach, a randomly selected
sub-cohort of non-cases will be selected from the main
cohort and used to compare risk factors for any or all
adverse outcomes.
Case–control studies enable the assessment of whether
exposures to specific drugs are associated with an
increased frequency of specific, major malformations.
The protocol enables assessment of the additional risk of
adverse outcomes consequential to drug exposure.
Confounding is addressed through the use of multi-
variate analysis, where the sample size is adequate. Alter-
natively, cases and controls can be matched in order to
address the potential for confounding. Subsequent ana-
lyses will therefore use paired statistical methods. In the
uncommon situation where the underlying condition
being treated and the suspected drug/s give rise to the
same adverse birth outcome or birth defect, the issue of
confounding by indication arises. In such instances,
assessing the differences in risk profile for different
drugs used to treat the same condition could assist in
addressing this potential confounding.
At the point of analysis, for both the exposed and the
unexposed comparison group, the pre-defined inclusion/
exclusion criteria for major congenital anomalies need to
be used to specify which features count as major malfor-
mations. To include minor features as “major” abnor-
malities unfairly and inappropriately exaggerates the
apparent fetal effects of an exposure [20]. This makes it
essential that studies of potential teratogens set inclu-
sion/exclusion criteria in advance of analysis to evaluate
the test group. The same criteria must be used to evalu-
ate their unexposed comparison group. Therefore, inclu-
sions and exclusions are not conducted at sentinel sites
but by the International Birth Defects Panel of experts,
without prior knowledge of group/exposure. Sentinel
sites are encouraged to report all anomalies (major and
minor) and all birth outcomes regardless of the type or
severity of such anomalies, whereas the Birth Defects
Panel adjudicates the defect as major or minor.The background risk of major congenital anomalies and
other adverse birth outcomes (e.g. stillbirths/miscarriage/
abortion) at sites is estimated from the proportion of
major anomalies and other adverse outcomes identified in
newborns of women who report no inter-current clinical
condition or exposure to potentially teratogenic medica-
tion during the relevant stage of pregnancy. Analyses
should be carried out for drug exposures in all three tri-
mesters as well as for the first trimester only. As the num-
ber of enrolled women increases over time, sub-analyses
that assess the safety of individual medicines or combin-
ation therapies becomes possible, as well as detailed ana-
lysis based on dose and duration of exposure.
Descriptive statistics are the primary approach for sum-
marizing data from pregnancy exposure registries with
frequencies of outcomes expressed via absolute risk, rela-
tive risk, and population attributable risk, with 95% confi-
dence intervals. Data collected through the Registry
should be evaluated with standard periodic reviews of the
database to assess the primary and secondary endpoints
as well as to assess the quality of the information submit-
ted by contributing sites based on pre-defined indicators
(e.g. missing data fields, inconsistencies between fields).
Statistical analysis should consider heterogeneity within
the data set in terms of methods employed, quality of the
data and other site-specific differences. If different meth-
ods of assessing drug exposure are used, analysis of out-
comes should be stratified by method (e.g. ANC card,
prescription, record linkage or self report), as some are
more precise than others.
Sample Size Calculations
The estimated sample size depends on the strength of
the teratogenic effect, the background frequency of ad-
verse pregnancy outcomes in the population of interest
as well as the number expected to be exposed to the
drugs under study, and the choice of comparator group
(background rate, or contemporaneous internal com-
parator) [21]. Much of this information is unknown in
the proposed settings for such a registry [22]. Therefore,
sample size should be finalized after the potential for
harm of a particular substance is characterized by an ini-
tial cohort of recruited women.
The background incidence of congenital anomalies is
established through a contemporaneous internal com-
parator group. Table 2 below describes two options for
estimating sample size based on case/comparators ratio:
1 case/ 1 comparator and 1 case/ 4 comparators. Two
options are also presented regarding the relative risk to
be detected (i.e. 2 or 10). Three different incidences of
risks are chosen in the comparator group. They corres-
pond to a baseline incidence of major malformations of
1% or 5%, and an incidence of 0.1% (which is generally
accepted incidence of the more common malformations)
Table 2 Sample size estimations based on background incidence, case/comparator ratio and anticipated relative risk
including continuity correction
1 case / 1 comparator 1 case / 4 comparators
RR to be detected : 2 RR to be detected : 10 RR to be detected : 2 RR to be detected : 10
Incidence in comparator group Cases Comparators Cases Comparators Cases Comparators Cases Comparators
5% 474 474 19 19 274 1096 10 40
1% 2515 2515 121 121 1445 5780 61 244
0.1% 25471 25471 1272 1272 14621 58484 628 2512
Mehta et al. BMC Pregnancy and Childbirth 2012, 12:89 Page 9 of 13
http://www.biomedcentral.com/1471-2393/12/89[21]. A continuity correction of 10% for the chi-squared
test has been included in the estimation.
Based on the calculations provided in Table 2, it can
be estimated that a cohort of at least 2515 exposed
women per drug of interest in the 1st trimester and an
equal number of comparison women would achieve a
power of 80 % to detect a doubling of risk of major birth
defects for any given drug of interest, assuming a back-
ground incidence of birth defects of 1% (excluding con-
genital anomalies, cardiovascular malformations and
genetic disorders which may not be detected) and a sig-
nificance level of P < 0.05. The sample size was calcula-
tion was calculated using WinPepi version 11.4 with
continuity correction.
Data management
The WHO Pregnancy Registry database has been devel-
oped using the free access software OpenClinica. The
database has been designed to accommodate electronic
and paper-based CRFs depending on the preferences of
the contributing sites.
Data entered on paper CRFs by health staff can be
subsequently entered into an electronic database. Inves-
tigators have experience with direct data entry into the
online OpenClinica database and with offline EPIdata
databases, with periodic transfer of both into a common
statistical package. The EPIdata programme is also an
open access standalone database but does not have an
audit trail. This can be provided to sites not requiring
an audit-trail and agreeing to routinely download the
data into the pooled Registry database. This multi-
pronged approach for data capture is intended to facili-
tate data capture at sites where online connectivity and
feasibility of electronic data capture approaches may be
limited, while ensuring ease of electronic data capture
where such infrastructure exists.
Future steps envisaged are to ensure that CRFs are
adapted for data capture using mobile phones and other
hand held electronic devices. Depending on the ap-
proach adopted by the site, systems can be supported at
the sites to ensure the integrity of the data capture and
contributions to a pooled Registry database.
Pre-defined searches, reports and analyses from the
pooled Registry will be developed in collaboration withsites and countries in order to facilitate routine analysis
of data by sites, countries and internationally. Pre-
defined analyses for determination of drug effect will be
agreed by contributing sites and investigators before
publication. National coordinators and research sites
agreeing to pool data into the database can be trained to
import data from the database into statistical packages
such as Stata and SPSS.Feedback and communication
The Registry is an opportunity to build trust and confi-
dence in the communities it serves. ANC staff should in-
form communities that they will be monitoring safety of
treatments during pregnancy. This will reduce the likeli-
hood of rumors and allay fears.
Through the automated online login system, pre-
designed tables and reports can be generated to provide
indicators of maternal and child health to the relevant
authorities and interest groups on a regular basis. Simi-
larly, routine progress reports by the registry investiga-
tors to the facility staff can ensure ongoing feedback.Discussion
A Pregnancy Registry is critical when the extent of
human reproductive risk remains unknown for an effect-
ive medication, thus either excluding an important
group from treatment, or increasing their risk. In im-
portant diseases – HIV and malaria as examples– the
potential for inadvertent exposure of the fetus to treat-
ment is high and may occur during early organogenesis,
when women may not be aware that they are pregnant.
In Sub-Saharan Africa, where 68% of the world’s HIV
population reside and approximately 25 million pregnant
women are at risk of P falciparum infection [23,24], the
major components of first line treatments for malaria
and HIV - artemisinins and efavirenz - are contraindi-
cated in the 1st trimester. Termination of pregnancy is
not a legal or cultural option in many African countries,
and hence exposure of pregnant women to medications
that may increase the risk of birth defects could cause
patient anxiety or illegal induced termination of a preg-
nancy. When exposure has not occurred, a pragmatic
approach in pregnancy involves either use of a less
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change which may be more costly.
Recent modeling studies projecting the clinical bene-
fits and risks of using EFV versus NVP to women of
childbearing age suggest that the survival gains through
use of EFV-based initial regimens in HIV-positive US
women of childbearing age would be small [25]. How-
ever, in Sub-Saharan Africa, modelling determines that
the survival gain of using EFV instead of NVP would
substantially outweigh the additional number of birth
defects [26]. This is based on current nevirapine and
EFV toxicity data and birth defect rates from the Anti-
retroviral Pregnancy Registry and excludes benefits from
the prevention of transmission to infants. WHO guide-
lines for PMTCT recognize that while data rule out a
10-fold or higher increase in risk with first-trimester
EFV exposure, it will take time to establish safety using
large numbers because even an elevated risk is likely to
be less than 1% [6].
Pregnancy registries minimize the penalties of limited
evidence by obtaining systematic, reliable data on whether
important drugs are teratogenic by monitoring exposure
in large enough numbers to provide levels of confidence
regarding hazard or benefit. This WHO Pregnancy Regis-
try protocol for assessing the risk of teratogenicity of
medicines in pregnancy has been piloted in five develop-
ing countries: Brazil, Ghana, Kenya, Tanzania and
Uganda; testing is still ongoing in Brazil and beginning
elsewhere. The approach has proven to be simple and
feasible in typical resource-constrained settings. The
methods are pragmatic and have been devised to support
and improve maternal and neonatal care, provide imme-
diate benefit to pregnant women, and complement and
build capacity of reproductive health staff to provide bet-
ter care – all of which increase the sustainability of the
approach. The generalizability of the methods across
countries enables data to be pooled.
There are three important features of this WHO Preg-
nancy Registry protocol which stand out from most other
registries. The first is the simplicity of including women
agreeing to take part at their first facility visit for care dur-
ing the pregnancy. This not only represents the popula-
tion of pregnant women coming for care but also enables
later comparison of birth defects among women who
have been exposed to a medicine with those who have
not. The second feature is the generic applicability of the
approach irrespective of drug or disease, and the third is
improvement of staff capacity to manage and monitor
pregnancies and newborns. These qualities add to the
practicality and cost-effectiveness of the protocol.
In developed countries there are systems in place to
monitor pregnancies and their outcomes. These data pro-
vide a population that can be compared with birth defect
prevalence in cohorts exposed to specific drugs [27]. Inthe United States, a prevalence of 1.5-2.5% major birth
defects at birth has been reported [28,29], a rate which
includes heart defects, hip dysplasia and cleft palate. In
resource-poor countries, population data on maternal
outcomes and malformations are very limited [11].
Hence, determination of any additional risk associated
with drug exposure in developing countries requires col-
lection of data on the baseline risk of birth defects in the
same population. By enrolling women as they come to
ANC care and assigning them to the exposed or unex-
posed population at the end of pregnancy, the assessment
of the prevalence of birth defects in a disease-negative,
unexposed population can be determined and becomes
directly comparable with prevalence of birth defects in a
disease-positive, treated population.
A second benefit is that this registry provides infor-
mation on many medications and health conditions
simultaneously; its value and sustainability exceed the
timeframe of safety-assessment for a specific drug. Not
only can teratogenic potential of the disease or maternal
condition (e.g. HIV, epilepsy, dengue) itself be determined
[30,31], but the disease plus treatment effects in the same
population can be evaluated. Importantly, the data can be
augmented over time by increasing the number of con-
tributing countries and sentinel sites adding data on the
effect size in different populations, and strengthening
levels of confidence in the results. Indeed, the power of
the approach lies in its broad application to a variety of
settings in which women may have more than one infec-
tious disease or condition during the course of the preg-
nancy and may also have been exposed to many drugs.
A third benefit is capacity building for improvement of
reproductive health. Although the objective of the WHO
Pregnancy Registry is to assess the safety of medicines to
which pregnant women are exposed, its prospective na-
ture and the requirement for any sentinel site contribut-
ing data to have or create an ANC program that meets
certain maternal and neonatal care standards, strengthens
its value for monitoring and managing these important
outcomes. In the optimal Registry scenario, women come
early to ANC in pregnancy, diagnostic capacity for dis-
eases is linked to records at the ANC clinic, ANC, peri-
natal and postnatal records are linked and precise data on
treatment exposure are available, and all deliveries occur
at the facility. The Registry training modules and protocol
actively supports these features. Thus, the protocol and
its implementation represent a novel way of monitoring
reproductive health, collecting important indicators of
maternal and neonatal health and service delivery and
providing an opportunity to build capacity for maternal
and child healthcare through supporting the development
of diagnostic skills for congenital anomalies and the cre-
ation of teratology information services at different insti-
tutions in resource-poor settings.
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try is subject to several limitations. Key challenges and
limitations are poor data quality or poor medical and
drug histories arising from lapses in memory (particularly
due to late presentation to the first ANC visit) and the in-
adequacy of existing medical records to confirm reported
exposures to medicines – both of which limit precision of
whether and when drug exposure might have occurred. A
second limitation is the potential for losses to follow-up
because of home births – measures to minimize this
problem have been described earlier. It is possible that
higher losses occur for riskier pregnancies.
Any registry that requires consenting women to take
part has potential for selection bias; women consenting
might have different characteristics from those who do
not consent to take part [32]. A fourth limitation is that
where there is a high case load and a number of babies
are being examined concurrently, it is possible that even
major birth defects are missed, if the baby is not exam-
ined systematically. Lack of local expertise and limited
diagnostic capacity (e.g. chromosome analysis) at each of
the sites (and sometimes even nationally) precludes the
assessment of infants whose diagnosis cannot be
assessed from the review of photographs. Finally, hetero-
geneity of data quality, and the presence of unknown
confounders may pose challenges in the analysis of data
and the attribution of cause.
This protocol is not reliable or informative about early
pregnancy loss due to specific drug exposure. This is be-
cause only women with viable pregnancies come for ante-
natal care (the timing of first antenatal visit is later in
Sub-Saharan Africa than in other regions [33]), and be-
cause an acute infection (e.g. malaria) as well as other fac-
tors can cause pregnancy losses. The Registry is designed
to detect only anomalies visible from surface examina-
tions at birth. Birth defects arising from nutritional defi-
ciencies or genetic factors that affect neural-development
and internal organ systems are unlikely to be detected;
further elaboration of this study design and access to spe-
cific skills and equipment often available at a tertiary facil-
ity would be required for these purposes.
Finally, communication strategies around the safety
profile of medicines in pregnancy would need to reduce
potential for heightened fear and rumours around par-
ticular drugs or conditions. Efforts should be made to
communicate effectively with women providing factual
information, particularly in settings where exposure to
the drug with limited information on safety has already
occurred.
This protocol is supported by training materials that
have been tested in four African countries and in Brazil.
These are available on request from the corresponding
author to those intending to initiate a Pregnancy Regis-
try, particularly with a data-pooling agreement withWHO already in place enabling the country to benefit
from the data it collects, as well as from an international
effort. The Pregnancy Registry that involves systematic,
improved care and assessment of the woman during
pregnancy and her newborn at birth also provides a
robust source of evidence of the safety of medicines used
in pregnancy.
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Additional file 1: Case Record Form 1. Antenatal data sheet. Data
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the confirmatory assessment of the infant for the suspected birth defect.
To be completed by a relevant medical specialist (e.g. neonatologist,
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Additional file 4: Guidance on the use of medicines during
pregnancy. A note given to recruited women on the prudent use of
medicines during the course of the pregnancy.
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